JP2024523822A - フッ素化トリプタミン化合物、その類似体、及びそれを使用する方法 - Google Patents

フッ素化トリプタミン化合物、その類似体、及びそれを使用する方法 Download PDF

Info

Publication number
JP2024523822A
JP2024523822A JP2023574858A JP2023574858A JP2024523822A JP 2024523822 A JP2024523822 A JP 2024523822A JP 2023574858 A JP2023574858 A JP 2023574858A JP 2023574858 A JP2023574858 A JP 2023574858A JP 2024523822 A JP2024523822 A JP 2024523822A
Authority
JP
Japan
Prior art keywords
ethyl
fluoro
indol
amine
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574858A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022256554A5 (https=
JP2024523822A5 (https=
Inventor
ジェイソン ウォーラック
マイケル ダイベック
Original Assignee
セント ジョセフズ ユニバーシティー
コンパス パスファインダー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セント ジョセフズ ユニバーシティー, コンパス パスファインダー リミテッド filed Critical セント ジョセフズ ユニバーシティー
Publication of JP2024523822A publication Critical patent/JP2024523822A/ja
Publication of JPWO2022256554A5 publication Critical patent/JPWO2022256554A5/ja
Publication of JP2024523822A5 publication Critical patent/JP2024523822A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
JP2023574858A 2021-06-02 2022-06-02 フッ素化トリプタミン化合物、その類似体、及びそれを使用する方法 Pending JP2024523822A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163195943P 2021-06-02 2021-06-02
US63/195,943 2021-06-02
US202163288313P 2021-12-10 2021-12-10
US63/288,313 2021-12-10
PCT/US2022/032000 WO2022256554A1 (en) 2021-06-02 2022-06-02 Fluorinated tryptamine compounds, analogues thereof, and methods using same

Publications (3)

Publication Number Publication Date
JP2024523822A true JP2024523822A (ja) 2024-07-02
JPWO2022256554A5 JPWO2022256554A5 (https=) 2025-06-03
JP2024523822A5 JP2024523822A5 (https=) 2025-06-03

Family

ID=84324579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574858A Pending JP2024523822A (ja) 2021-06-02 2022-06-02 フッ素化トリプタミン化合物、その類似体、及びそれを使用する方法

Country Status (11)

Country Link
US (1) US20240286998A1 (https=)
EP (1) EP4347559A4 (https=)
JP (1) JP2024523822A (https=)
KR (1) KR20240017363A (https=)
AU (1) AU2022287013A1 (https=)
BR (1) BR112023025340A2 (https=)
CA (1) CA3220850A1 (https=)
CO (1) CO2023018652A2 (https=)
IL (1) IL308944A (https=)
MX (1) MX2023014437A (https=)
WO (1) WO2022256554A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326048A (en) 2021-09-03 2026-03-01 Alexander Shulgin Res Institute Inc Asymmetric allyl tryptamines
WO2023147424A1 (en) * 2022-01-27 2023-08-03 Terran Biosciences, Inc. Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine
US12157722B1 (en) * 2023-08-03 2024-12-03 Gilgamesh Pharmaceuticals, Inc. Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
CN121866243A (zh) * 2023-09-07 2026-04-14 耶路撒冷希伯来大学伊森姆研究发展有限公司 致幻化合物、其制备方法及其用途
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506736A (ja) * 1995-06-06 1999-06-15 シェーリング コーポレイション ニューロキニンアンタゴニストとしての置換ベンゼン縮合ヘテロ環および炭素環
WO1999047516A1 (en) * 1998-03-16 1999-09-23 Abdelmalik Slassi 3-(2-pyrrolidinylmethyl)-indole compounds having 5-ht6 affinity
JP2000508670A (ja) * 1996-04-18 2000-07-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ピペリジン化合物およびピロリジン化合物
JP2002531556A (ja) * 1998-12-08 2002-09-24 ハー・ルンドベック・アクチエゼルスカベット ベンゾフラン誘導体、その製造方法及びその使用方法
JP2006510595A (ja) * 2002-09-12 2006-03-30 ワイス 複素環縮合ベンゾジオキサンメチルアミンの抗うつ作用性インドールアルキル誘導体
WO2019222552A1 (en) * 2018-05-16 2019-11-21 University Of Florida Research Foundation Methods and compositions for substituted 2,5-diketopiperazine analogs
JP2020506246A (ja) * 2017-02-09 2020-02-27 カームテック、エルエルシー シロシビン誘導体を含む組成物及び方法
WO2020245133A1 (en) * 2019-06-03 2020-12-10 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
WO2021155467A1 (en) * 2020-02-04 2021-08-12 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders
US20220041551A1 (en) * 2020-02-18 2022-02-10 Gilgamesh Pharmaceuticals, Inc. Methods of treating mood disorders
WO2022047579A1 (en) * 2020-09-01 2022-03-10 Magicmed Industries Inc. Halogenated psilocybin derivatives and methods of using
WO2022061242A1 (en) * 2020-09-20 2022-03-24 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement
WO2022120475A1 (en) * 2020-12-07 2022-06-16 Mindset Pharma Inc. 3-cyclic amine-indole derivatives as serotonergic agents for the treatment of cns disorders

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506736A (ja) * 1995-06-06 1999-06-15 シェーリング コーポレイション ニューロキニンアンタゴニストとしての置換ベンゼン縮合ヘテロ環および炭素環
JP2000508670A (ja) * 1996-04-18 2000-07-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ピペリジン化合物およびピロリジン化合物
WO1999047516A1 (en) * 1998-03-16 1999-09-23 Abdelmalik Slassi 3-(2-pyrrolidinylmethyl)-indole compounds having 5-ht6 affinity
JP2002531556A (ja) * 1998-12-08 2002-09-24 ハー・ルンドベック・アクチエゼルスカベット ベンゾフラン誘導体、その製造方法及びその使用方法
JP2006510595A (ja) * 2002-09-12 2006-03-30 ワイス 複素環縮合ベンゾジオキサンメチルアミンの抗うつ作用性インドールアルキル誘導体
JP2020506246A (ja) * 2017-02-09 2020-02-27 カームテック、エルエルシー シロシビン誘導体を含む組成物及び方法
US10933073B2 (en) * 2017-02-09 2021-03-02 Caamtech Llc Compositions and methods comprising a psilocybin derivative
WO2019222552A1 (en) * 2018-05-16 2019-11-21 University Of Florida Research Foundation Methods and compositions for substituted 2,5-diketopiperazine analogs
WO2020245133A1 (en) * 2019-06-03 2020-12-10 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
WO2021155467A1 (en) * 2020-02-04 2021-08-12 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders
US20220041551A1 (en) * 2020-02-18 2022-02-10 Gilgamesh Pharmaceuticals, Inc. Methods of treating mood disorders
WO2022047579A1 (en) * 2020-09-01 2022-03-10 Magicmed Industries Inc. Halogenated psilocybin derivatives and methods of using
WO2022061242A1 (en) * 2020-09-20 2022-03-24 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement
WO2022120475A1 (en) * 2020-12-07 2022-06-16 Mindset Pharma Inc. 3-cyclic amine-indole derivatives as serotonergic agents for the treatment of cns disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"PubChem CID 67394638", CREATE DATE: 2012年11月30日, JPN6026005229, 2012, ISSN: 0005791930 *
MAGNE, V. ET AL.: ""Synthesis of Spiroindolenines via Regioselective Gold(I)-Catalyzed Cyclizations of N-Propargyl Try", ADVANCED SYNTHESIS & CATALYSIS, vol. 359, no. 22, JPN6026005230, 2017, pages 4036 - 4042, ISSN: 0005791931 *

Also Published As

Publication number Publication date
WO2022256554A1 (en) 2022-12-08
MX2023014437A (es) 2024-03-08
KR20240017363A (ko) 2024-02-07
CA3220850A1 (en) 2022-12-08
BR112023025340A2 (pt) 2024-02-20
AU2022287013A1 (en) 2023-12-07
EP4347559A1 (en) 2024-04-10
IL308944A (en) 2024-01-01
EP4347559A4 (en) 2025-04-09
CO2023018652A2 (es) 2024-01-25
US20240286998A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
JP2024523822A (ja) フッ素化トリプタミン化合物、その類似体、及びそれを使用する方法
CN102906091B (zh) 苦参酸/碱衍生物及其制备方法和用途
EP3962601B1 (en) 5-ht2a agonists for use in treatment of depression
CN106163516A (zh) 异吲哚啉组合物和治疗神经变性疾病的方法
JPH08109169A (ja) 非ペプチドタキキニン受容体拮抗物質
KR102442536B1 (ko) 리나글립틴 결정형 및 이의 제조방법
JP6130828B2 (ja) キナゾリンジオン誘導体
TW201018467A (en) Novel compounds as calcium channel blockers
US20240254087A1 (en) Selective, partial, and arrestin-biased 5-ht2a agonists with utility in various disorders
KR101406736B1 (ko) 아고멜라틴 히드로브로마이드 히드레이트 및 이의 제법
US12319682B2 (en) Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists
JP2012102018A (ja) アミド化合物
JP2025504791A (ja) ヒドロキシフェニル部分を含む化合物及びその使用
US8530453B2 (en) Compounds and methods for the treatment of pain and other diseases
AU2020270992B2 (en) D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
CN117957211A (zh) 氟化色胺化合物、其类似物及其使用方法
AU2023206823A1 (en) Crystal of substituted piperidine compound, salts of substituted piperidine compound, and crystals thereof
US12338231B1 (en) N-heterocycle substituted tryptamine derivatives and methods of using
JP2026067907A (ja) 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
TW202608881A (zh) 咪唑稠環類化合物、藥物組成物及其製備方法和用途
CN121969606A (zh) 化合物
WO2014190942A1 (zh) 一类吲哚类化合物、其制备方法、药物组合物及应用
CN118284607A (zh) 用于治疗疾病和障碍的lsd衍生物、合成和方法
Hillver et al. Synthesis and pharmacology of the enantiomers of UH301: Opposing interactions with 5‐HT1A receptors
HK40016699B (zh) 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260212